Previous Close | 25.24 |
Open | 24.90 |
Bid | 24.83 x 900 |
Ask | 24.87 x 1400 |
Day's Range | 24.63 - 25.06 |
52 Week Range | 16.02 - 36.95 |
Volume | |
Avg. Volume | 551,211 |
Market Cap | 1.988B |
Beta (5Y Monthly) | 1.71 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for MYGN
Myriad Genetics (MYGN) posts better-than-expected results in Q2 with contributions from most product lines.
Myriad (MYGN) delivered earnings and revenue surprises of 100% and 6.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.